相关实验视频

Updated: Jan 10, 2026

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

埃弗罗利斯可以改善前额叶皮层ADNP倒退的小鼠的认知缺陷和突触功能障碍

Yu Xiang¹, Zeyu Zhang², Yunrui Jiang¹

¹Department of Neurology, Shanxi Provincial People's Hospital, Taiyuan 030012, China; Shanxi Key Laboratory of Brain Disease Control, Shanxi Provincial People's Hospital, Taiyuan 030012, China.

Neuroscience letters

|November 20, 2025

概括

活动依赖神经保护蛋白 (ADNP) 缺乏会损害大脑功能,导致自闭症谱系障碍 (ASD) 和智力障碍 (ID). 在小鼠模型中,Everolimus (EVR) 治疗改善了认知缺陷和分子变化.

科学领域:

神经科学是一个神经科学.
遗传学遗传学是一种遗传学.
分子生物学分子生物学

背景情况:

活动依赖神经保护蛋白 (ADNP) 对大脑发育和认知至关重要,其功能障碍与自闭症谱系障碍 (ASD) 和智力障碍 (ID) 有关.
mTORC1过度激活会负面调节自,这种过程在ASD中经常受到影响.
拉巴胺素的衍生物Everolimus (EVR) 在临床上使用,可以挽救一些与ASD相关的行为,但其在ADNP相关的病理学中的有效性尚未被探索.

研究的目的:

研究ADNP缺乏在前额叶皮层 (PFC) 的行为和分子后果.
为了确定EVR治疗是否可以改善与ADNP缺乏相关的表型,在小鼠模型中.

主要方法:

建立前额叶皮层 (PFC) ADNP淘汰 (KD) 鼠标模型.
评估行为缺陷 (学习,记忆,焦虑) 和分子变化 (mTORC1通路,自,微管和突触蛋白).
为了评估治疗效果,每天给予腹腔内EVR (5 mg/kg).

主要成果:

在PFC中ADNPKD导致mTORC1通路激活,自性损伤,学习和记忆缺陷以及焦虑类行为.
在ADNP KD小鼠中观察到微管和突触蛋白的失调.
每日EVR治疗显著缓解了ADNP缺乏引起的行为和分子异常.

结论:

在PFC中ADNP缺乏引发了与ASD和ID相关的分子和行为缺陷.
EVR有效地挽救了这些缺陷,这表明mTOR途径是ADNP相关认知障碍的治疗目标.

关键词:

在此之前,ADNP是ADNP.这是Everolimus.这些微管是微管子.突触 (Synapses) 是一个突触的组成部分.在mTOROR中使用mTOR.

更多相关视频

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus

Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus

Published on: June 17, 2015

相关概念视频

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...